Follow
Mario Scartozzi
Mario Scartozzi
Verified email at unica.it
Title
Cited by
Cited by
Year
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
J Clin Oncol 27 (16), 2622-2629, 2009
5062009
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
M Scartozzi, E Galizia, S Chiorrini, R Giampieri, R Berardi, C Pierantoni, ...
Annals of oncology 20 (2), 227-230, 2009
3852009
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with …
M Scartozzi, I Bearzi, R Berardi, A Mandolesi, G Fabris, S Cascinu
Journal of clinical oncology 22 (23), 4772-4778, 2004
3282004
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, ...
Annals of Oncology 23 (9), 2313-2318, 2012
2162012
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
S Cascinu, R Berardi, R Labianca, S Siena, A Falcone, E Aitini, S Barni, ...
The lancet oncology 9 (1), 39-44, 2008
1742008
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
G Marisi, A Cucchetti, P Ulivi, M Canale, G Cabibbo, L Solaini, FG Foschi, ...
World journal of gastroenterology 24 (36), 4152, 2018
1642018
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy
M Scartozzi, I Bearzi, C Pierantoni, A Mandolesi, F Loupakis, A Zaniboni, ...
Journal of clinical oncology 25 (25), 3930-3935, 2007
1552007
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study
M Scartozzi, L Faloppi, G Svegliati Baroni, C Loretelli, F Piscaglia, ...
International journal of cancer 135 (5), 1247-1256, 2014
1432014
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches
M Scartozzi, E Galizia, F Freddari, R Berardi, R Cellerino, S Cascinu
Cancer treatment reviews 30 (5), 451-459, 2004
1212004
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
M Scartozzi, R Giampieri, E Maccaroni, M Del Prete, L Faloppi, ...
British journal of cancer 106 (5), 799-804, 2012
1202012
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy
C Madeddu, M Deidda, A Piras, C Cadeddu, L Demurtas, M Puzzoni, ...
Journal of cardiovascular medicine 17, e12-e18, 2016
1182016
HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research
F Pietrantonio, M Caporale, F Morano, M Scartozzi, A Gloghini, F De Vita, ...
International journal of cancer 139 (12), 2859-2864, 2016
1142016
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable …
S Cascinu, M Scartozzi, R Labianca, V Catalano, RR Silva, S Barni, ...
British journal of cancer 90 (8), 1521-1525, 2004
1062004
Immunotherapy for colorectal cancer: where are we heading?
D Basile, SK Garattini, M Bonotto, E Ongaro, M Casagrande, M Cattaneo, ...
Expert opinion on biological therapy 17 (6), 709-721, 2017
1042017
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta …
C Solinas, M Ceppi, M Lambertini, M Scartozzi, L Buisseret, S Garaud, ...
Cancer treatment reviews 57, 8-15, 2017
1032017
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ...
Oncotarget 7 (41), 67142, 2016
1032016
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
L Faloppi, M Scartozzi, M Bianconi, G Svegliati Baroni, P Toniutto, ...
BMC cancer 14, 1-8, 2014
1012014
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
M Scartozzi, M Bianconi, L Faloppi, C Loretelli, A Bittoni, M Del Prete, ...
British journal of cancer 108 (5), 1126-1132, 2013
962013
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
AC Gardini, L Faloppi, S De Matteis, FG Foschi, N Silvestris, F Tovoli, ...
European Journal of Cancer 86, 106-114, 2017
942017
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
A Gnoni, N Silvestris, A Licchetta, D Santini, M Scartozzi, R Ria, S Pisconti, ...
Critical reviews in oncology/hematology 95 (1), 46-61, 2015
942015
The system can't perform the operation now. Try again later.
Articles 1–20